文献速递临床生化临床免疫

迈瑞hs-cTnT(CLIA)检测的性能评估

Performance evaluation of a new high-sensitivity cardiac troponin T assay: hs-cTnT (CLIA) assay.
PubMed 文献 · Clin Chem Lab Med · 2025-11-26

本研究评估迈瑞新型高敏心肌肌钙蛋白T化学发光免疫分析(CLIA)的分析与临床性能,在895名健康人中建立性别特异性第99百分位上限,并在559例疑似急性心肌梗死患者中与罗氏hs-cTnT检测对比。结果显示该检测精密度好、灵敏度高(LoD 1.4 ng/L、LoQ 2.4 ng/L),临床诊断性能与罗氏Gen 5相当。

要点

  • 该检测满足高敏检测标准,总体可测值比例91.48%。
  • 性别特异性第99百分位上限为男性18.6 ng/L、女性9.6 ng/L、总体16.0 ng/L。
  • 临床队列敏感性100.0%、特异性83.3%、AUC 0.988,与罗氏Gen 5相当。

核心结论

  • 迈瑞hs-cTnT(CLIA)检测满足高敏检测标准,分析与诊断性能稳健,可作为罗氏Gen 5检测评估心肌损伤的可靠替代方案。

研究设计与样本

  • 研究评估迈瑞hs-cTnT(CLIA)检测的分析性能(精密度、灵敏度、线性、样本类型比较、方法学比较及潜在干扰)。
  • 在895名健康个体中建立性别特异性第99百分位参考上限。
  • 在559例疑似急性心肌梗死患者中评估临床诊断性能,并与罗氏hs-cTnT检测比较。

主要发现

  • 重复性CV≤1.99%,实验室内精密度CV≤6.11%。
  • LoD为1.4 ng/L,LoQ为2.4 ng/L,线性r=0.9978。
  • 按厂家声称LoD 2.0 ng/L计,可测值在男性中占99.36%、女性中占83.26%、总体占91.48%。
  • 临床队列敏感性100.0%、特异性83.3%、PPV 80.0%、NPV 100.0%、AUC 0.988。

关键数值与推荐

  • 性别特异性第99百分位上限:男性18.6 ng/L、女性9.6 ng/L、总体16.0 ng/L。
  • 重复性CV≤1.99%,实验室内精密度CV≤6.11%;LoD 1.4 ng/L,LoQ 2.4 ng/L;线性r=0.9978。
  • 临床诊断性能:敏感性100.0%、特异性83.3%、PPV 80.0%、NPV 100.0%、AUC 0.988。

临床怎么用

  • 该检测可用于疑似急性心肌梗死患者的心肌损伤评估,其诊断性能与罗氏Gen 5 hs-cTnT检测相当。
  • 临床应用时应采用本检测建立的性别特异性第99百分位上限(男性18.6 ng/L、女性9.6 ng/L)判读结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Fourth Universal Definition of Myocardial Infarction recommends high-sensitivity cardiac troponin (hs-cTn) as the preferred biomarker for diagnosing myocardial infarction. This study evaluated the analytical and clinical performance of a novel hs-cTnT chemiluminescence immunoassay (CLIA) developed by Mindray. METHODS: Analytical performance characteristics including precision, sensitivity (limit of detection [LoD] and limit of quantification [LoQ]), imprecision profile, linearity, sample type comparison, method comparison, and potential interferences were assessed. Sex-specific 99th percentile upper reference limits (URLs) were established in 895 healthy individuals. Clinical diagnostic performance was evaluated in 559 patients with suspected acute myocardial infarction and compared with the Roche hs-cTnT assay. RESULTS: The Mindray assay showed excellent precision (repeatability CV≤1.99 %, within-laboratory precision CV≤6.11 %), superior sensitivity (LoD: 1.4 ng/L; LoQ: 2.4 ng/L), and linearity (r=0.9978), along with robust performance against common and immunological interferences. Using the manufacturer-claimed LoD of 2.0 ng/L, measurable values were found in 99.36 % of males, 83.26 % of females, and 91.48 % overall, meeting criteria for high-sensitivity assays. The derived sex-specific 99th percentiles were 18.6 ng/L (males), 9.6 ng/L (females), and 16.0 ng/L (overall). In the clinical cohort, the assay showed 100.0 % sensitivity, 83.3 % specificity, 80.0 % PPV, 100.0 % NPV, and an AUC of 0.988, comparable to the Roche Gen 5 hs-cTnT assay. CONCLUSIONS: The Mindray hs-cTnT (CLIA) assay meets high-sensitivity assay criteria and demonstrates robust analytical and diagnostic performance, offering a reliable alternative to the Roche Gen 5 assay for clinical evaluation of myocardial injury.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Shu X, Zhang C, Deng T, et al. Performance evaluation of a new high-sensitivity cardiac troponin T assay: hs-cTnT (CLIA) assay. Clin Chem Lab Med. 2025. PMID: 41288507. doi:10.1515/cclm-2025-1258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。